Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
about
BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alphaLithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cellsTumor refractoriness to anti-VEGF therapyThe Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory DiseasesTumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsStructural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response.Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerA phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabBlocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia.Utilizing a high-throughput microfluidic platform to study hypoxia-driven mesenchymal-mode cell migration.Selection, Analysis and Improvement of Anti-Angiogenesis Compounds Identified by an Anti-HIF-1α Screening and Validation System.Mechanisms of glioma-associated neovascularization.Anticancer agents that counteract tumor glycolysis.Comparison of diffuse optical tomography of human breast with whole-body and breast-only positron emission tomography.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.Front instabilities and invasiveness of simulated avascular tumorsImpaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.Hypoxia inducible factors in hepatocellular carcinomaHypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia.Strategies targeting angiogenesis in advanced non-small cell lung cancer.Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine.
P2860
Q24303563-470A8D1D-7B72-4329-8909-B0C469A77C06Q24617423-8DD8B32C-7E4A-4F12-B835-5318DDF59F17Q26747678-E364661B-1436-416B-B0BA-EBB643D8CCB4Q26749138-CC384591-2C56-464D-8EAB-BAEDD54B891AQ26774355-EC3BF623-673D-4ECF-967E-4AC8A2E5E27EQ27638869-FFCA1328-D72D-42D0-B5F5-18998B84D4CAQ28068654-06D2C834-678E-470F-BFB5-BE85797D6B26Q33397006-84EB791C-0302-4F77-AF3E-2C4624F99E2BQ33414685-1D93BA5F-61B9-4F9A-B05F-6629C0C08B84Q33418562-FD1E2EB3-7DBF-4C99-9EF9-7807627E9DBAQ33628057-42764342-33D7-4494-917A-82F4D25D0BC4Q34786452-011EBA61-B9F0-4BA0-9270-3BF95A33CE63Q35766225-52C526DF-F4DC-458F-8EF8-66D490D397C9Q36201751-72C0FF79-B477-4039-97DD-C980F52AA228Q36295477-F593AA1A-38B5-441A-9F7C-09B08342017FQ36452381-EBF4DA61-46BD-4ED4-8717-4BE67F8B6C67Q36774229-8876978C-42CD-4721-B850-B3A40C360ABDQ36926098-ACFB51A2-5892-4994-8EF0-67765713E778Q37268981-0F699B9E-9D49-46F8-8A40-1165D18A45CBQ37337096-85FBFD6F-772A-4408-8848-C1C67E0E3324Q37439146-C4F13F6E-B6E8-40C4-86E9-849328D56131Q37565283-C53D0718-8128-4EF6-95B0-1822D0C5DC55Q37807243-37707727-5BCA-41C4-A885-6FD774363516Q38685135-D1C3B08C-13DC-497F-B68F-ECA7835B71F5Q39698671-FD09B6B4-9EFB-426D-8587-F9ED774F4149Q41593429-37159458-D12F-4661-9A4C-499F5ED34149Q42862829-8A8CC831-31E5-43DD-B5C5-0D39C376D90F
P2860
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
@ast
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
@en
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy
@nl
type
label
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
@ast
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
@en
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy
@nl
prefLabel
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
@ast
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
@en
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy
@nl
P356
P1476
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review)
@en
P2093
M V Blagosklonny
P304
P356
10.3892/IJO.19.2.257
P577
2001-08-01T00:00:00Z